Navigation Links
Blocking Glucocorticoid Prevents Stress-Induced Skin Abnormalities

Inhibiting glucocorticoid, a type of steroid, can prevent skin abnormalities induced by psychological stress, according to a new study from the December //issue of the American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. The new study also shows how psychological stress induces skin abnormalities that could initiate or worsen skin disorders such as psoriasis and atopic dermatitis.

Previous research has shown that psychological stress increases glucocorticoid production. In addition, it is well recognized that psychological stress adversely affects many skin disorders, including psoriasis and atopic dermatitis.

“In this study, we showed that the increase in glucocorticoids induced by psychological stress induces abnormalities in skin structure and function, which could exacerbate skin diseases,” Feingold explained. This provides a link for understanding how psychological stress can adversely affect skin disorders. Blocking the production or action of glucocorticoids prevented the skin abnormalities induced by psychological stress.

Skin protects

The skin is the body’s largest organ and plays a crucial role in providing a barrier between the environment and the internal organs. It protects us from harmful microorganisms, ultraviolet light, toxic chemicals, and more. However, its most important function is providing a permeability barrier that prevents us from drying out. We are approximately 65 percent water and we are able to survive and function in dry environments because the skin forms a permeability barrier that prevents the loss of water.

The permeability barrier is located in the outermost layer of the epidermis, the stratum corneum. The stratum corneum is composed of dead cells surrounded by lipid membranes which mediate the permeability barrier. The stratum corneum layer continuously sloughs off, and therefore must be regenerated. The epidermal cells in the lower epi
'"/>




Page: 1 2 3

Related medicine news :

1. Blocking Pain Found To Slow Down The Healing Process
2. Improving The Survival Of Lung Cancer Patients By Blocking The Effects Of Estrogen
3. Protein Fragments Blocking Cures Alzheimers Disease
4. Multiple Sclerosis Can Be Treated By Blocking Fat Hormone
5. Ventilation Systems Not Effective in Blocking Tobacco Smoke
6. Study Says - Blocking aP2 Protein Prevents Airway Diseases
7. Sunscreen Blocking UVA Radiation Receives Federal Approval
8. New Cancer-Blocking Algae Found
9. Glucocorticoid in ‘bad Light’ During Fertility Treatmet
10. Harmful Effects Of Glucocorticoids On Newborns Owing To Prenatal Exposure
11. Tea Prevents Skin Cancer
Post Your Comments:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 1NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 2NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 3NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 52659 4SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 1SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 2SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 3SAPHRIS 28R 29 28asenapine 29 Meets Primary Endpoint in Long Term Extension Study in Patients With Predominant Persistent Negative Symptoms of Schiz 13189 4Terumo Cardiovascular Systems Initiates U S Clinical Trial for Anaconda 28TM 29 AAA Stent Graft System 4777 1Terumo Cardiovascular Systems Initiates U S Clinical Trial for Anaconda 28TM 29 AAA Stent Graft System 4777 2